ResMed makes another timely software purchase

Article Excerpt

ResMed’s Software-as-a-Service (SaaS) segment provides software solutions aimed at letting medial professionals and out-of-hospital care agencies work more efficiently to deliver personalized care. It’s a significant growth area for the company. RESMED INC., $218.05, is a buy. The company (New York symbol RMD; TSINetwork Rating: Average) (www.resmed.com; Shares outstanding: 146.9 million; Market cap: $32.5 billion; Dividend yield: 0.8%) continues to make acquisitions to expand its SaaS offerings. It’s now buying privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. The purchase price has not yet been disclosed. Somnoware software aims to streamline the process of diagnosing and evaluating a patient’s sleep and respiratory care test results, among other key functions. Somnoware electronically provides this information, placing it directly into a patient’s electronic health record—all from within the Somnoware platform. Overall, the SAAS business currently contributes just 11% of ResMed’s revenue, but represents a strong growth area and a relationship builder with physicians and sleep and pulmonary-function testing labs. ResMed is a buy. buy. …